title: Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity.
abstract: The fat-soluble prohormone cholecalciferol (Vitamin D3) is a precursor of the circulating 25-OH Vitamin D3, which is converted by 1α-hydroxylase to the biologically active 1,25-OH Vitamin D3. Active Vitamin D3 interacts with the Vitamin D receptor (VDR), a transcription factor that plays an important role in calcium mobilization and bone formation. RUNX2 is a DNA-binding transcription factor that regulates target genes important in bone formation, angiogenesis, and cancer metastasis. Using computer-assisted drug design (CADD) and a microtiter plate-based DNA-binding enzyme-linked immunosorbent assay (D-ELISA) to measure nuclear RUNX2 DNA binding, we have found that Vitamin D3 prohormones can modulate RUNX2 DNA binding, which was dose-dependent and sensitive to trypsin, salt, and phosphatase treatment. Unlabeled oligonucleotide or truncated, dominant negative RUNX2 proteins were competitive inhibitors of RUNX2 DNA binding. The RUNX2 heterodimeric partner, Cbfβ, was detected in the binding complexes with specific antibodies. Evaluation of several RUNX2:DNA targeted small molecules predicted by CADD screening revealed a previously unknown biological activity of the inactive Vitamin D3 precursor, cholecalciferol. Cholecalciferol modulated RUNX2:DNA binding at nanomolar concentrations even in cells with low VDR. Cholecalciferol and 25-OH Vitamin D3 prohormones were selective inhibitors of RUNX2-positive endothelial, bone, and breast cancer cell proliferation, but not of cells lacking RUNX2 expression. These compounds may have application in modulating RUNX2 activity in an angiogenic setting, in metastatic cells, and to promote bone formation in disease-mediated osteoporosis. The combination CADD discovery and D-ELISA screening approaches allows the testing of other novel derivatives of Vitamin D and/or transcriptional inhibitors with the potential to regulate DNA binding and biological function.
authors.affiliation: The Marlene & Stewart Greenebaum Cancer Center, University of Maryland School of Medicine, Baltimore, MD, USA.
authors.forename: Karen F
authors.initials: KF
authors.lastname: Underwood
authors.forename: David R
authors.initials: DR
authors.lastname: D'Souza
authors.forename: Maria
authors.initials: M
authors.lastname: Mochin-Peters
authors.forename: Adam D
authors.initials: AD
authors.lastname: Pierce
authors.forename: Sravya
authors.initials: S
authors.lastname: Kommineni
authors.forename: Moran
authors.initials: M
authors.lastname: Choe
authors.forename: Jessica
authors.initials: J
authors.lastname: Bennett
authors.forename: Averell
authors.initials: A
authors.lastname: Gnatt
authors.forename: Bahru
authors.initials: B
authors.lastname: Habtemariam
authors.forename: Alexander D
authors.initials: AD
authors.lastname: MacKerell
authors.forename: Antonino
authors.initials: A
authors.lastname: Passaniti
mesh_terms: D002112:Calcifediol / Q000494:pharmacology; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D002762:Cholecalciferol / Q000494:pharmacology*; D050659:Core Binding Factor Alpha 1 Subunit / Q000378:metabolism*; D050658:Core Binding Factor beta Subunit / Q000378:metabolism; D004247:DNA / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D057809:HEK293 Cells; D006801:Humans; D007700:Kinetics; D008958:Models, Molecular; D011485:Protein Binding / Q000187:drug effects; D018167:Receptors, Calcitriol / Q000378:metabolism
chemical_list: D050659:Core Binding Factor Alpha 1 Subunit; D050658:Core Binding Factor beta Subunit; C493709:RUNX2 protein, human; D018167:Receptors, Calcitriol; D002762:Cholecalciferol; D004247:DNA; D002112:Calcifediol